Petra Den Hollander, PhD
Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine
Present Title & Affiliation
Primary Appointment
Instructor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA, PHD, Biomedical Sciences |
| 2002 | Vrije Universiteit Amsterdam, Amsterdam, MS, Biomedical Sciences |
Postgraduate Training
| 2010-2013 | Research Fellowship, Triple Negative Breast Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2007-2010 | Research Fellowship, Breast Cancer Genomics, Baylor College of Medicine, Houston, TX |
Experience & Service
Academic Appointments
Instructor, Department of Clinical Cancer Prevention - Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2015
Other Appointments/Responsibilities
Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2002
Honors & Awards
| 2013 | Finalist of the DFI Mentored Junior Faculty Fellowship, MDACC |
| 2008 | Poster Presentation Finalist, Baylor College of Medicine |
| 2005 | AFLAC Travel Award (AFLAC), AACR |
| 2005 | Trainee Excellence Award, MDACC |
| 2001 | Scholar in Training Award (GlaxoSmithKline), AACR |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, Mani SA. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene 35(46):5977-5988, 2016. e-Pub 2016. PMID: 27292262.
- Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat 158(3):441-54, 2016. e-Pub 2016. PMID: 27393618.
- den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res 76(7):1942-53, 2016. e-Pub 2016. PMID: 26921331.
- Toneff MJ, Sreekumar A, Tinnirello A, Hollander PD, Habib S, Li S, Ellis MJ, Xin L, Mani SA, Rosen JM. The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states. BMC Biol 14:47, 2016. e-Pub 2016. PMID: 27317311.
- Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73(11):3470-80, 2013. e-Pub 2013. PMID: 23633491.
- den Hollander P, Savage MI, Brown PH. Targeted Therapy for Breast Cancer Prevention. Front Oncol 3:250, 2013. e-Pub 2013. PMID: 24069582.
- Hampton OA, Koriabine M, Miller CA, Coarfa C, Li J, den Hollander P, Schoenherr C, Carbone L, Nefedov M, Ten Hallers BF, Lee AV, De Jong PJ, Milosavljevic A. Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. Cancer Genet 204(8):447-57, 2011. PMID: 21962895.
- Hampton OA, den Hollander P, Miller CA, Delgado DA, Li J, Coarfa C, Harris RA, Richards S, Scherer SE, Muzny DM, Gibbs RA, Lee AV, Milosavljevic A. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 19(2):167-77, 2009. e-Pub 2008. PMID: 19056696.
- Fontenot DR, den Hollander P, Vela EM, Newman R, Sastry JK, Kumar R. Dynein light chain 1 peptide inhibits human immunodeficiency virus infection in eukaryotic cells. Biochem Biophys Res Commun 363(4):901-7, 2007. e-Pub 2007. PMID: 17919453.
- den Hollander P, Rayala SK, Coverley D, Kumar R. Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. Cancer Res 66(22):11021-9, 2006. PMID: 17108141.
- Rayala SK, den Hollander P, Manavathi B, Talukder AH, Song C, Peng S, Barnekow A, Kremerskothen J, Kumar R. Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells. J Biol Chem 281(28):19092-9, 2006. e-Pub 2006. PMID: 16684779.
- den Hollander P, Kumar R. Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells. Cancer Res 66(11):5941-9, 2006. PMID: 16740735.
- Gururaj AE, Singh RR, Rayala SK, Holm C, den Hollander PP, Zhang H, Balasenthil S, Talukder AH, Landberg G, Kumar R. MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A 103(17):6670-5, 2006. e-Pub 2006. PMID: 16617102.
- Rayala SK, den Hollander P, Balasenthil S, Molli PR, Bean AJ, Vadlamudi RK, Wang RA, Kumar R. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem 281(7):4395-403, 2006. e-Pub 2005. PMID: 16352611.
- Rayala SK, den Hollander P, Balasenthil S, Yang Z, Broaddus RR, Kumar R. Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep 6(6):538-44, 2005. PMID: 15891768.
- Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 5(6):575-85, 2004. PMID: 15193260.
- Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95(3):198-205, 2003. PMID: 12569141.
- Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 7(10):3127-34, 2001. PMID: 11595705.
Grant & Contract Support
| Title: | PTP4A3 is critical for the early progression of triple-negative breast cancer |
| Funding Source: | MDACC DFI |
| Role: | Principal Investigator |
| Title: | Era of Hope Postdoctoral Fellowship |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Research Training Grant |
| Funding Source: | Dutch Cancer Society |
| Role: | Principal Investigator |